Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy.

showed a positive trend in PFS and OS from the addition of Cx to CT in patients who had experienced a Grade 1 skin rash compared with patients with Grade 0 skin rash. 25 A recently published study confirmed a correlation between Grade 3 skin toxicity emerged within 90 days from starting Cx therapy and benefit in OS in R/M HNSCC. 26 Generally, targeted therapy holds great promise to improve patients’ outcome while limiting toxicity as compared with CT.

also in 11,005 other papers